The Top 5 Biosimilar Articles for the Week of January 13

Number 5: Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.

Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis, paving the way for improved accessibility and cost savings in osteoporosis treatment.

Number 3: Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market entry.

Number 2: Sarfaraz K. Niazi argues that the Indian Central Drugs Standard Control Organisation (CDSCO) Biosimilar Guidelines need revision to align with current scientific understanding and focus on better manufacturing practices.

Number 1: The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving visual acuity in patients with diabetic macular edema (DME), with comparable efficacy, safety, pharmacokinetics, and immunogenicity at 24 weeks, with more long-term data expected.

To read all of these articles and more, visit centerforbiosimilars.com.